NEURO-ONCOLOGY. Abstracts. P02.05. CLINICAL STUDY PHASE II WITH DENDRITIC CELL. VACCINATION AND TUMOUR LYSATE AS ADD-ON THERAPY.
Neuro-Oncology 16:ii1 – ii112, 2014. doi:10.1093/neuonc/nou174
NEURO-ONCOLOGY
Abstracts
P02.05. CLINICAL STUDY PHASE II WITH DENDRITIC CELL VACCINATION AND TUMOUR LYSATE AS ADD-ON THERAPY IN HIGH GRADE GLIOMA G. Stragliotto1, S. Holm2, L. Adamson3, G. Giraud2, and J.I. Henter2; 1Dept of Neurology Karolinska University Hospital, Stockholm, Sweden; 2Dept of Pediatrics Karolinska University Hospital, Stockholm, Sweden; 3Dept of Oncology Pathology Karolinska University Hospital, Stockholm, Sweden
intradermally, a technique which has been developed by van Gool et al in Leuven, Belgium. METHODS: Adult patients underwent leukaferesis after radical surgery. The DC were extracted by CD14+ enrichement with the CliniMacs platform. Blood samples for immunologic stimulation analysis (CD4, CD8) were collected prior to therapy and before each intradermal vaccination. RESULTS: Since December 2009, DCm-HGG-L has been produced at the Karolinska University Hospital for HGG patients, according to a GMP protocol required by the Medical Product Agency. Twelve patients have been treated, 6 with de novo glioblastoma, 4 with recurrent high grade glioma, one with recurrent PNET, and one with recurrent rhabdoid tumor. Age 2 and 20-50 yr, KPS 70-100. All underwent radical surgery followed by radiochemotherapy. Median PFS , 6 mo (3-18 m) for 6 patients. OS: 2 patients with recurrent tumor died between 3-6 months after treatment, three other are alive without recurrence at 1 year. The child has been treated for , 6 mo. De novo GBM OS is . 2 yrs. The CD4 and CD8 blasts increased and remained at high level after the 3 rd vaccine. CONCLUSION: The immunological therapy for High Grade Glioma is safe. Further evaluation is under way to implement this strategy, especially in the adult population.
AIM: To improve treatment of high-grade glioma (HGG) with immune therapy based on vaccination with autologous dendritic cells (DC) loaded with tumour-derived lysate (DCm-HGG-L). BACKGROUND: Immune therapy of CNS tumours is an emerging modality that potentially can enhance the current multimodal treatment approaches being used. This autologous vaccine is both tumour-specific and well tolerated, given
Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2014.
